Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30177 ↗At a glance
Leserbrief in Pediatric Blood & Cancer, 2023. Written by Nazaret Sánchez-Sierra and 8 co-authors. Institution: Department of Pediatric Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Neoplasms, Neoplasms, Germ Cell and Embryonal. Cited 2 times so far (Crossref); 22 references.
Topics: Mobilisation
Abstract (original language)
To the Editor: Non-germinomatous germcell tumors (NGGCTs) account for one-third of all intracranial germ cell tumors (GCTs).1 These tumors predominate in adolescents in pineal and suprasellar regions.2,3 Despite the combination of chemotherapy and radiotherapy, prognosis in NGGCTs remains dismal (60%–70% overall survival).4,5 High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (autoHSCT) could be part of the upfront or relapsed treatment of some pediatric brain tumors.6,7 However, there is limited information on the use of syngeneic hematopoietic stem cell transplantation (sHSCT). We report the outcome of a male with an intracranial NGGCT and a peripheral blood stem-cell (PBSC)mobilization failurewho received an sHSCT from his identical twin brother. A 13-year-old male presented with a year of headache, diplopia, polyuria, and polydipsia. A craniospinal magnetic resonance imaging revealed two masses located in the suprasellar and pineal regions, with secondary hydrocephalus without leptomeningeal dissemination. Beta-human chorionic gonadotropin (bHCG) was 46.1 IU/L in serum and 197.9 IU/L in cerebrospinal fluid (CSF). Alpha-fetoprotein was negative in both. Due to the markers and the radiological findings, the patient was diagnosed with a bifocal NGGCT without histological confirmation. He received the induction treatment according to the SIOP-CNS-GCT-II protocol for standard-risk NGGCT. A small residual mass and the elevation of bHCG in the CSF (6.3I U/L) persisted afterwards. A complete resection of the tumor was performed and one cycle of HDCT was planned. PBSC mobilization and apheresis were attempted using subcutaneous granulocytic colony-stimulating factor (G-CSF) 5 μg/kg every 12 hours for 4 days. The flow cytometry performed on day 4, showed 0.32 CD34+/mm3, less than the target to start the apheresis (>10CD34+/mm3). He received onemore day of GCSF and a single dose of plerixafor 0.24 mg/kg 10 hours before the apheresis. Despite this treatment, our patient presented 0.56 CD34+/mm3. As he had a twin brother, we offered the patient and the family to perform an sHSCT. To confirm syngenecity, red blood cell genotype, hematopoietic chimerism, and PCR analysis using 16 microsatellite markers of several chromosomes were performed using PPlex 16 Sytem-Promega (Madison WI, USA) (Figure 1). The donor and his parents were informed about the procedure and both signed the informed consent. Two ultrasound-guided peripheral lines were used. Although the donor was a minor (14-year old), PBSC mobilized with G-CSF was prioritized for rapid hematological recovery. He received subcutaneous G-CSF 5 μg/kg every 12 hours for 4 days, subsequently presenting 16.62 CD34+/mm3 analyzed by flow cytometry. The device used in the leukapheresis procedure was SPECTRA OPTIA of TERUMOBCT, using the CMNC (Continuous Collection of Mononuclear Cells) program. A total of 15,085 ml of whole blood was processed (volume patient= 4310ml). The collected product had a volume of 242ml, and collection efficiency CE= 79.04%. The final count of product apheresis collection was 2.4 × 106 CD34/kg in the first day, with no severe side effects of themobilization. The patient received HDCT based on SIOP-CNS-GCT-II guidelines and a non-manipulated syngeneic graft (Table 1). Given the cellularity of the product (2.4 × 106 CD34/kg), he received subcutaneous G-CSF from day+5 to 2 days after reaching the white blood cell graft (day+9) as well as corticosteroid prophylaxis of the engraftment syndrome. As main complications, he developed Escherichia coli sepsis, grade 3 hyperemesis, and mucositis. Antiviral and antibiotic prophylaxis was discontinued 4 months after sHSCT. The patient continued treatment as planned with focal proton beam radiation therapy. He ended treatment 8months after diagnosis and is currently in complete remission. HDCT followed by autoHSCT rescue has shown efficacy and may improve long-term survival in children diagnosed with some recurrent and chemosensitive brain tumors,8,9 as GCTs.10,11 Phase I and II studies of HDCT have been published to find the optimal combination of chemotherapeutic agents and their dose in these children.12–14 Nevertheless, mobilization failures can happen in patients who received intensive chemotherapy before the apheresis. The possibility to perform a syngeneic transplant in these cases is very rare but should be taken into consideration if a twin donor is available. The experience reported with these types of transplants, especially in these tumors, is anecdotical. Previous experiences with sHSCT in patients with refractory immune-mediated diseases,15–17 myelodysplastic syndromes,18 aplastic anemia,19 lymphomas,20 and some aggressive solid tumors in adults21,22 have shown a rapid and sustained bone marrow engraftment and a very low incidence of graft-versus-host disease (GVHD). However, the use of syngeneic transplantation in children with brain tumors have not previously been reported. sHSCT may offer advantages over autoHSCT such as a longer remission15,19 without increasing toxicity.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pediatric Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain.
- Neuro-Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.
- Transfusion Service, Banc de Sang i Teixits, Hospital Sant Joan de Déu, Barcelona, Spain.
- Department of Molecular Genetics, Hospital Sant Joan de Déu, Barcelona, Spain.
- Haematology Department, Hospital Clínic, Barcelona, Spain.
- Stem Cell Transplant Unit and Department of Hematology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain.
ORCID profiles: Nazaret Sánchez-Sierra, Marta Perez-Somarriba, Vicente Santa-Maria
Cite
APA
Sánchez-Sierra, N., Perez-Somarriba, M., Santa-Maria, V., Cruz, O., García-Rey, E., Martorell, L., Rovira, M., Margarit, A., & Marsal, J. (2023). Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30177
Vancouver
Sánchez-Sierra N, Perez-Somarriba M, Santa-Maria V, Cruz O, García-Rey E, Martorell L, et al. Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30177
BibTeX
@article{SnchezSierra2023,
author = {Sánchez-Sierra, Nazaret and Perez-Somarriba, Marta and Santa-Maria, Vicente and Cruz, Ofelia and García-Rey, Enric and Martorell, Loreto and Rovira, Montserrat and Margarit, Adriana and Marsal, Julia},
title = {Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30177}
}
EUVIMED